Achieve Life Sciences, Inc. (ACHV) Cash Flow Statement
Achieve Life Sciences, Inc. (ACHV) generated -$47.0M of operating cash flow over the twelve months to 2026-06-30, spent $2.5M on capital expenditure and had free cash flow of -$49.5M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ACHVAchieve Life Sciences, Inc.Follow ACHV — free
—
Price chart with a free account
- Market cap
- 667.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -20.3 | -43.5 | -35.9 | -17.3 | -0.4 | -0.2 | -9.1 | -10.6 | -15.2 | -13.5 | -29.4 | -37.6 | -24.5 | -29.8 | -49.5 | -47.0 | |
| Capital expenditure | 0.1 | 0.3 | 0.3 | 0.1 | 0.4 | 0.0 | — | 0.0 | 0.1 | 0.0 | — | — | 0.0 | — | 0.0 | -2.5 | |
| Free cash flow | -20.3 | -43.8 | -36.2 | -17.4 | -0.7 | -0.2 | — | -10.7 | -15.3 | -13.5 | — | — | -24.5 | — | -49.5 | -49.5 | |
| Stock-based compensation | 1.2 | 2.2 | 2.8 | 3.9 | 2.3 | 1.6 | 0.3 | 0.9 | 1.2 | 1.3 | 2.2 | 3.3 | 3.4 | 5.3 | 8.8 | — |
USD millions · SEC XBRL
Achieve Life Sciences, Inc. — questions
- What is Achieve Life Sciences, Inc.'s operating cash flow?
- -$47.0M over the twelve months to 2026-06-30.
- How much does Achieve Life Sciences, Inc. spend on capital expenditure?
- $2.5M over the twelve months to 2026-06-30.
- What is Achieve Life Sciences, Inc.'s free cash flow?
- -$49.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Achieve Life Sciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.